6/17/2010

Flibanserin, Boehringer Ingelheim's drug candidate for sexual dysfunction in women, caused only slight improvement in postmenopausal women with hypoactive sexual desire disorder, FDA reviewers reported. A Boehringer official said the firm continues to believe in clinical data demonstrating the safety and efficacy of flibanserin "in balancing the chemicals in the brain linked to sexual desire." The drug will be reviewed by an FDA panel Friday.

Full Story:
CNN

Related Summaries